MGTX

In April 2026, MeiraGTx reacquired full rights to the bota-vec eye disease program from Janssen Pharmaceuticals. The company reported its first-quarter 2026 financial and operational results and announced an inducement grant in May 2026. In June 2026, it secured a strategic investment of up to $400 million from Oberland Capital to support the development and commercialization of AAV2-hAQP1 and bota-vec. MeiraGTx reported its second-quarter 2026 financial and operational results and announced another inducement grant in August 2026. As of October 2026, the stock price was $11.11 per share, marking a 34.67% increase from September 29, 2025, despite recent fluctuations including a -7.57% weekly fall and a -22.45% monthly fall. Analysts have a consensus price target of $24.71, suggesting a potential upside of approximately 137.9% from its October 8, 2026 price of $10.39.